Do you want to read an article? Please log in or register.
HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration
Macular Diseases
Related content
COMMENTED
Macular Diseases
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study
Am J Ophthalmol.
Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, Dong X, Zhang M, Xing Y, Zhu S, Chen X, Shen Y, Huang H, Yu L, Ke Z, Rosenfeld PJ, Kaiser PK, Ying G, Sun X, Xu X; PHOENIX Study Group.
doi: 10.1016/j.ajo.
Macular Diseases
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
JAMA Ophthalmol.
Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU
doi: 10.1001/jamaophthalmol.
Macular Diseases
Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial
JAMA Ophthalmol.
Ramakrishnan MS, Yu Y, VanderBeek BL
doi: 10.1001/jamaophthalmol.2019.4577.
Macular Diseases
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study
Ophthalmology.
Kunimoto D, Yoon YH, Wykoff CC, Chang A, Khurana RN, Maturi RK, Agostini H, Souied E, Chow DR, Lotery AJ, Ohji M, Bandello F, Belfort R Jr, Li XY, Jiao J, Le G, Schmidt W, Hashad Y, CEDAR and SEQUOIA Study Groups.
doi: 10.1016/j.ophtha.2020.03.035.
Macular Diseases
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
JAMA Ophthalmol.
Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S
doi: 10.1001/jamaophthalmol.
Macular Diseases
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials
JAMA Ophthalmol.
Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell PM, Tufail A, Brittain C, Ferrara D, Gray S, Honigberg L, Martin J, Tong B, Ehrlich JS, Bressler NM, for the Chroma and Spectri Study Investigators
COMMENTED
Macular Diseases
Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Ophthalmology
Holekamp NM, Campochiaro PA, Chang M, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C, Archway Investigators.
doi: 10.1016/j.ophtha.2021.09.016
Macular Diseases
Association Between Cilioretinal Arteries and Advanced Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT)
JAMA Ophthalmol.
Bavinger JC, Ying GS, Daniel E, Grunwald JE, Maguire MG, Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.
doi: 10.1001/jamaophthalmol.
Macular Diseases
Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol.
Hsu J, Patel SN, Wolfe JD, Shah CP, Chen E, Jenkins TL, Wibbelsman TD, Obeid A, Mikhail M, Garg SJ, Ho AC, Chiang A, Spirn MJ, Vander JF
doi: 10.1001/jamaophthalmol.2020.0724.